LivaNova PLC
↗London, United Kingdom
LivaNova is a global medical technology company focused on developing innovative solutions for the 'Head and Heart.' The company operates primarily through two segments: Neuromodulation, which provides VNS Therapy for drug-resistant epilepsy and difficult-to-treat depression, and Cardiopulmonary, which offers advanced technologies for cardiac surgery, including heart-lung machines and oxygenation systems.
Formed in 2015 through the merger of Cyberonics (USA) and Sorin S.p.a. (Italy), LivaNova maintains a global presence with operational headquarters in the United States and corporate headquarters in London, UK. The company is committed to improving patient outcomes through bioelectronic therapies and advanced surgical technologies, supported by a workforce of approximately 3,000 employees.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:-
Industry:Medical Devices
Sub-Industry:Neuromodulation and Cardiopulmonary
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1.39B
Founded:2015
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:LIVN
Market Cap:$3.47B
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Medical Device Company)
Modalities:Neuromodulation, Medical Devices
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Various clinical research partnerships for VNS Therapy and cardiopulmonary innovation.
COMPETITION
Position:Leader
Competitors:NeuroPace, Medtronic, Boston Scientific, Edwards Lifesciences
LEADERSHIP
Key Executives:
Vladimir Makatsaria - CEO
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of LivaNova PLC and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with LivaNova PLC. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.